CN101797235A - Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof - Google Patents
Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof Download PDFInfo
- Publication number
- CN101797235A CN101797235A CN 201010129075 CN201010129075A CN101797235A CN 101797235 A CN101797235 A CN 101797235A CN 201010129075 CN201010129075 CN 201010129075 CN 201010129075 A CN201010129075 A CN 201010129075A CN 101797235 A CN101797235 A CN 101797235A
- Authority
- CN
- China
- Prior art keywords
- sodium sulfonate
- carbazochrome sodium
- disintegrating tablets
- oral disintegrating
- correctives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses carbazochrome sodium sulfonate oral disintegrating tablets and a preparation method thereof. The carbazochrome sodium sulfonate oral disintegrating tablets are prepared from the following components in percentage by mass: 1-15% of carbazochrome sodium sulfonate, 50-90% of filler, 5-40% of disintegrant, 1-8% of adhesive, 0.1-5% of lubricant and 0.1-5% of flavoring agent. The oral disintegrating tablets have the advantages of smooth surface, attractive appearance, moderate hardness, quick absorption, quick effect taking, small liver first-pass effect, high bioavailability, little irritation to the gastrointestinal tract, favorable mouthfeel and convenient taking, can quickly disintegrate in the oral cavity without water, is particularly suitable for aged people, children, patients in bed or with dysphagia, and especially for bleeding patients inconvenient to drink water during or after operations. The oral disintegrating tablets are prepared in a wet-method pelletizing tabletting way. The preparation method has the advantages of simple production technology, stable and easily-controlled preparation quality, and low cost, and is suitable for industrial large-scale production.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, particularly a kind of carbazochrome sodium sulfonate oral disintegrating tablets also relates to the preparation method of this oral cavity disintegration tablet.
Background technology
Tablet have steady quality, dosage accurately, take and advantages such as easy to carry, production mechanization degree height, production cost are low, be one of at present the most frequently used pharmaceutical dosage form.But disintegrate is slow, bioavailability is lower, part patient swallows than deficiencies such as difficulties because of it exists simultaneously, is subjected to restriction to a certain degree on using.In recent years, novel troches such as oral cavity disintegration tablet, dispersible tablet and Sublingual tablet continue to bring out.Oral cavity disintegration tablet is a kind of water disintegrate or dissolved tablet fast of not needing in the oral cavity, have fast, rapid-action, the advantages such as liver first-pass effect is little, bioavailability is high, GI irritation is little, taking convenience of absorption, be particularly suitable for the patient of old man, child, bed, dysphagia or drinking-water inconvenience.
Carbazochrome sodium sulfonate (Carbazochrome Sodium Sulfonate), chemical name is 1-methyl-6-oxo-2,3,5,6-tetrahydro indole-5-semicarbazone-2-sulfonate sodium trihydrate, be that Japanese Tanabe Mitsubishi Pharmaceutical Co takes the lead in researching and developing successful hemorrhage of new generation, have advantages such as haemostatic effect is good, onset rapid, effect is lasting, toxic and side effects is little, be mainly used in urinary system, upper digestive tract, respiratory tract and department of obstetrics and gynecology hemorrhagic disease, comparatively remarkable to the urinary system curative effect, also can be used for the prevention of operative hemorrhage and treatment etc.
Carbazochrome sodium sulfonate
The preparation type that carbazochrome sodium sulfonate has gone on the market mainly contains conventional tablet, capsule, powder, granule, injection and injection powder pin etc., has not yet to see the oral cavity disintegration tablet listing, does not also see the correlational study report.
Summary of the invention
In view of this, one of purpose of the present invention is to provide a kind of carbazochrome sodium sulfonate oral disintegrating tablets, and two of purpose is to provide a kind of preparation method of described carbazochrome sodium sulfonate oral disintegrating tablets.
For achieving the above object, the present invention adopts following technical scheme:
1, carbazochrome sodium sulfonate oral disintegrating tablets, composed of the following components by mass percentage: carbazochrome sodium sulfonate 1%~15%, filler 50%~90%, disintegrating agent 5%~40%, binding agent 1%~8%, lubricant 0.1%~5% and correctives 0.1%~5%.
Further, composed of the following components by mass percentage: carbazochrome sodium sulfonate 1%~10%, filler 65%~85%, disintegrating agent 5%~20%, binding agent 2%~6%, lubricant 0.1%~1% and correctives 0.4%~1.5%;
Further, composed of the following components by mass percentage: carbazochrome sodium sulfonate 8%~9%, filler 74%~80%, disintegrating agent 6%~12%, binding agent 3%~5%, lubricant 0.4%~0.5% and correctives 0.4%~1.0%;
Further, described filler is one or more in starch, pregelatinized Starch, dextrin, Icing Sugar, lactose, mannitol, xylitol, erythritol and the microcrystalline Cellulose; Described disintegrating agent is one or more in low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, polyvinylpolypyrrolidone and the gas-producing disintegrant, and gas-producing disintegrant is made up of tartaric acid, citric acid or fumaric acid and sodium bicarbonate or sodium carbonate; Described binding agent is one or more in starch, methylcellulose, ethyl cellulose and the hydroxypropyl methylcellulose; Described lubricant is one or more in magnesium stearate, Pulvis Talci and the micropowder silica gel; Described correctives is one or more in saccharin sodium, aspartame, steviosin and the Mentholum;
Further, described filler is one or more in starch, mannitol and the microcrystalline Cellulose; Described disintegrating agent is polyvinylpolypyrrolidone and/or gas-producing disintegrant; Described binding agent is a hydroxypropyl methylcellulose; Described lubricant is a magnesium stearate; Described correctives is Mentholum and/or aspartame;
Further, described filler is starch, mannitol and microcrystalline Cellulose; Described disintegrating agent is polyvinylpolypyrrolidone or polyvinylpolypyrrolidone and gas-producing disintegrant, and gas-producing disintegrant is made up of citric acid and sodium bicarbonate; Described correctives is Mentholum or Mentholum and aspartame.
2, the preparation method of described carbazochrome sodium sulfonate oral disintegrating tablets adopts the wet granule compression tablet method, may further comprise the steps:
A, pulverizing: filler, disintegrating agent, binding agent, lubricant and correctives pulverize separately are become the fine powder of fineness more than 100 orders;
B, granulation: with carbazochrome sodium sulfonate and partially filled dose of mixing, pulverize, cross 80 mesh sieves; Again with the residue filler, in disintegrating agent, binding agent, in add the correctives mixing, cross 80 mesh sieves; Add wetting agent system soft material again, 20~40 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 20~60 mesh sieve granulate;
C, tabletting: with the dried granule behind the step b granulate with add disintegrating agent, lubricant, add the correctives mixing, tabletting promptly gets carbazochrome sodium sulfonate oral disintegrating tablets.
Further, the wetting agent among the described step b is that volume fraction is 60% ethanol water;
Further, adopt 24 mesh sieves to granulate among the described step b, dried granule is crossed 24 mesh sieve granulate.
Beneficial effect of the present invention is: carbazochrome sodium sulfonate oral disintegrating tablets any surface finish of the present invention, attractive in appearance, and hardness is suitable; Needn't use water delivery service, saliva can make its rapidly disintegrate in the oral cavity, and taking convenience is particularly suitable for the patient of old man, child, bed or dysphagia, especially in the operation or postoperative hemorrhage and the patient of the inconvenience of drinking water; Cool taste, sweetness, exquisiteness, the patient is easy to accept, and drug compliance is good; Medicine after the disintegrate has considerable part directly to absorb through the oral cavity except that part enters the gastrointestinal tract with swallowing act, and rapid-action, liver first-pass effect is little, the bioavailability height; Entering the gastrointestinal medicine is homodisperse fine particle, is large tracts of land and distributes in gastrointestinal tract, and absorption point increases, and local excitation reduces to gastrointestinal; The present invention adopts the wet granule compression tablet legal system to be equipped with carbazochrome sodium sulfonate oral disintegrating tablets, and production technology is simple, and the stable easily control of the quality of the pharmaceutical preparations is with low cost, is fit to large-scale industrialization production.
The present invention is " Chongqing City's veterinary drug Engineering Technical Research Centre " research project.
The specific embodiment
In order to make the purpose, technical solutions and advantages of the present invention clearer, will be described in detail the preferred embodiments of the present invention below.
Carbazochrome sodium sulfonate oral disintegrating tablets of the present invention, composed of the following components by mass percentage:
Carbazochrome sodium sulfonate: 1%~15%, preferred 1%~10%, more preferably 8%~9%;
Filler: 50%~90%, preferred 65%~85%, more preferably 74%~80%;
Disintegrating agent: 5%~40%, preferred 5%~20%, more preferably 6%~12%;
Binding agent: 1%~8%, preferred 2%~6%, more preferably 3%~5%;
Lubricant: 0.1%~5%, preferred 0.1%~1%, more preferably 0.4%~0.5%;
Correctives: 0.1%~5%, preferred 0.4%~1.5%, more preferably 0.4%~1.0%.
Described filler is selected from one or more in starch, pregelatinized Starch, dextrin, Icing Sugar, lactose, mannitol, xylitol, erythritol and the microcrystalline Cellulose, in preferred starch, mannitol and the microcrystalline Cellulose one or more, more preferably mannitol, starch and microcrystalline Cellulose.Starch property is highly stable, low price, and hygroscopicity is little, and water absorption is strong and certain dilatancy is arranged, and is applicable to water-insoluble or microsolubility medicine.Mannitol is soluble in water, stable in properties, and no hygroscopicity, sugariness is equivalent to 70% of sucrose approximately, and heat absorption during because of dissolving has refrigerant sense when dissolving in the oral cavity.Microcrystalline Cellulose is water insoluble, have good flowability and compressibility, except that lubricating and disintegration as also having concurrently the filler, during with the strong low-substituted hydroxypropyl cellulose of swelling behavior, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, polyvinylpolypyrrolidone use in conjunction, can improve the porosity of tablet, strengthen capillarity, make tablet disintegrate fast in low amounts of water.
Described disintegrating agent is selected from one or more in low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, polyvinylpolypyrrolidone and the gas-producing disintegrant, preferred polyvinylpolypyrrolidone and/or gas-producing disintegrant, more preferably polyvinylpolypyrrolidone or polyvinylpolypyrrolidone and gas-producing disintegrant.Polyvinylpolypyrrolidone has very high capillary activity and hydratability, can rapidly water be absorbed in the tablet, and when internal pressure is the intensity that swelling power surpasses tablet, disintegrate promptly takes place tablet, is efficient tablet disintegrant.Gas-producing disintegrant is made up of organic acid and weak base, and carbon dioxide makes the quick disintegrate of tablet thereby soda acid is met water reaction generation.In the present invention, described gas-producing disintegrant preferably is made up of tartaric acid, citric acid or fumaric acid and sodium bicarbonate or sodium carbonate, more preferably is made up of citric acid and sodium bicarbonate.
Described binding agent is selected from one or more in starch, methylcellulose, ethyl cellulose and the hydroxypropyl methylcellulose, preferred hydroxypropyl methylcellulose.
Described lubricant is selected from one or more in magnesium stearate, Pulvis Talci and the micropowder silica gel, preferred magnesium stearate.
Because oral cavity disintegration tablet is disintegrate or dissolving in the oral cavity, so when the preparation oral cavity disintegration tablet, should be specifically noted that sensory issues.Added correctives in the oral cavity disintegration tablet of the present invention, described correctives is selected from one or more in saccharin sodium, aspartame, steviosin and the Mentholum, preferred aspartame and/or Mentholum, more preferably Mentholum or aspartame and Mentholum.
Carbazochrome sodium sulfonate oral disintegrating tablets of the present invention adopts the preparation of wet granule compression tablet method, may further comprise the steps:
A, pulverizing: filler, disintegrating agent, binding agent, lubricant and correctives pulverize separately are become the fine powder of fineness more than 100 orders;
B, granulation: with carbazochrome sodium sulfonate and partially filled dose of mixing, pulverize, cross 80 mesh sieves; Again with the residue filler, in disintegrating agent, binding agent, in add the correctives mixing, cross 80 mesh sieves; Add wetting agent system soft material again, 20~40 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 20~60 mesh sieve granulate;
C, tabletting: with the dried granule behind the step b granulate with add disintegrating agent, lubricant, add the correctives mixing, tabletting promptly gets carbazochrome sodium sulfonate oral disintegrating tablets.
When wet granule compression tablet, should note following some: (1) easily sticks on the machine when pulverizing separately because the water content of principal agent carbazochrome sodium sulfonate is about 15%, and a small amount of adhesion becomes strip and block, is difficult for sieving; Simultaneously, the water content of filler starch also higher (being generally 10%~15%) is mixed difficulty of pulverizing with principal agent, be difficult for sieving; Therefore, among the present invention starch with before should 100~105 ℃ in advance dry, make water content below 8%; Simultaneously,, pulverize, sieve, mix with other adjuvant again carbazochrome sodium sulfonate elder generation and dry starch mixing.(2) method that is routinely added to of disintegrating agent has three kinds: addition 1.: granulate behind disintegrating agent and other composition mix homogeneously, thereby make disintegrating agent be present in granule interior, though disintegrate is slower, once just beading of disintegrate, help stripping; 2. outer addition: disintegrating agent is added in the dried granule behind the granulate, thereby makes disintegrating agent be present in outside the granule and between each granule, after moisture content penetrated, disintegrate was rapid, but because of there not being disintegrating agent in the granule, easy disintegrating beading not, and stripping is poor slightly; 3. inside and outside addition: disintegrating agent is divided into two parts, and a by interior addition adding, another part adds by outer addition.Discover by single factor experiment,, more help the quick disintegrate of oral cavity disintegration tablet when disintegrating agent adds fashionablely by inside and outside addition.Therefore, the present invention adopts inside and outside addition to add disintegrating agent.Wherein, the adding method of gas-producing disintegrant is: will the wherein a kind of of bronsted lowry acids and bases bronsted lowry with other composition mix homogeneously after granulate, another kind is added in the dried granule behind the granulate, gives birth to reaction thereby avoid when wet granulation soda acid to meet waterishlogging.(3) because correctives such as Mentholum etc. have effumability, the present invention adds volatile correctives before being chosen in and granulating, and reduces its volatilization loss as far as possible, remains not volatile correctives and then adds after granulation, make made tablet outer sweet, easilier on mouthfeel accepted by the patient.
Discover, adopt the carbazochrome sodium sulfonate oral disintegrating tablets of above-mentioned supplementary material and method preparation, any surface finish, attractive in appearance, hardness is suitable, and disintegrate and pass through 30 mesh sieves fully in 30 seconds meets the requirement of oral cavity disintegration tablet in 37 ± 1 ℃ of water.
Embodiment 1
Prescription
All components pulverize separately during method for making will be write out a prescription except that carbazochrome sodium sulfonate becomes the fine powder of fineness more than 100 orders; 100~105 ℃ of dryings, make water content starch below 8%; With the carbazochrome sodium sulfonate and the dry starch mixing of recipe quantity, pulverize, cross 80 mesh sieves; Mix with mannitol, microcrystalline Cellulose, hydroxypropyl methylcellulose and the Mentholum of recipe quantity and the polyvinylpolypyrrolidone of 1/2 recipe quantity again, cross 80 mesh sieves; Add volume fraction again and be 60% ethanol water and make soft material in right amount, 24 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 24 mesh sieve granulate; The magnesium stearate that in dried granule, adds residue polyvinylpolypyrrolidone and recipe quantity again, mixing, tabletting is made 1000 of carbazochrome sodium sulfonate oral disintegrating tablets altogether, and every contains carbazochrome sodium sulfonate 10mg.
Quality gained oral cavity disintegration tablet any surface finish, attractive in appearance; Hardness is 22~27 Ns and pauses; 30 mesh sieves are also passed through in complete disintegrate in 24 seconds in 37 ± 1 ℃ of water; Taste and sweet mouthfeel, refrigerant, fine and smooth, no grittiness.
Embodiment 2
Prescription
All components pulverize separately during method for making will be write out a prescription except that carbazochrome sodium sulfonate becomes the fine powder of fineness more than 100 orders; 100~105 ℃ of dryings, make water content starch below 8%; With the carbazochrome sodium sulfonate and the dry starch mixing of recipe quantity, pulverize, cross 80 mesh sieves; Mix with mannitol, microcrystalline Cellulose, citric acid, hydroxypropyl methylcellulose and the Mentholum of recipe quantity and the polyvinylpolypyrrolidone of 1/2 recipe quantity again, cross 80 mesh sieves; Add volume fraction again and be 60% ethanol water and make soft material in right amount, 24 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 24 mesh sieve granulate; The sodium bicarbonate and the magnesium stearate that in dried granule, add residue polyvinylpolypyrrolidone and recipe quantity again, mixing, tabletting is made 1000 of carbazochrome sodium sulfonate oral disintegrating tablets altogether, and every contains carbazochrome sodium sulfonate 10mg.
Quality gained oral cavity disintegration tablet any surface finish, attractive in appearance; Hardness is 21~28 Ns and pauses; 30 mesh sieves are also passed through in complete disintegrate in 23 seconds in 37 ± 1 ℃ of water; Cool taste, sweetness, exquisiteness, no grittiness.
Embodiment 3
Prescription
All components pulverize separately during method for making will be write out a prescription except that carbazochrome sodium sulfonate becomes the fine powder of fineness more than 100 orders; 100~105 ℃ of dryings, make water content starch below 8%; With the carbazochrome sodium sulfonate of recipe quantity and dry starch mixing, pulverizing, cross 80 mesh sieves; Mix with mannitol, microcrystalline Cellulose, hydroxypropyl methylcellulose and the Mentholum of recipe quantity and the polyvinylpolypyrrolidone of 1/2 recipe quantity again, cross 80 mesh sieves; Add volume fraction again and be 60% ethanol water and make soft material in right amount, 24 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 24 mesh sieve granulate; The magnesium stearate and the aspartame that in dried granule, add residue polyvinylpolypyrrolidone and recipe quantity again, mixing, tabletting is made 1000 of carbazochrome sodium sulfonate oral disintegrating tablets altogether, and every contains carbazochrome sodium sulfonate 10mg.
Quality gained oral cavity disintegration tablet any surface finish, attractive in appearance; Hardness is 22~27 Ns and pauses; 30 mesh sieves are also passed through in complete disintegrate in 25 seconds in 37 ± 1 ℃ of water; Cool taste, sweetness, exquisiteness, no grittiness.
Embodiment 4
Prescription
All components pulverize separately during method for making will be write out a prescription except that carbazochrome sodium sulfonate becomes the fine powder of fineness more than 100 orders; 100~105 ℃ of dryings, make water content starch below 8%; With the carbazochrome sodium sulfonate of recipe quantity and dry starch mixing, pulverizing, cross 80 mesh sieves; Mix with mannitol, microcrystalline Cellulose, citric acid, hydroxypropyl methylcellulose and the Mentholum of recipe quantity and the polyvinylpolypyrrolidone of 1/2 recipe quantity again, cross 80 mesh sieves; Add volume fraction again and be 60% ethanol water and make soft material in right amount, 24 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 24 mesh sieve granulate; The sodium bicarbonate, magnesium stearate and the aspartame that in dried granule, add residue polyvinylpolypyrrolidone and recipe quantity again, mixing, tabletting is made 1000 of carbazochrome sodium sulfonate oral disintegrating tablets altogether, and every contains carbazochrome sodium sulfonate 10mg.
Quality gained oral cavity disintegration tablet any surface finish, attractive in appearance; Hardness is 17~27 Ns and pauses; 30 mesh sieves are also passed through in complete disintegrate in 28 seconds in 37 ± 1 ℃ of water; Cool taste, sweetness, exquisiteness, no grittiness.
Embodiment 5
Prescription
All components pulverize separately during method for making will be write out a prescription except that carbazochrome sodium sulfonate becomes the fine powder of fineness more than 100 orders; 100~105 ℃ of dryings, make water content starch below 8%; With the carbazochrome sodium sulfonate of recipe quantity and dry starch mixing, pulverizing, cross 80 mesh sieves; Mix with mannitol, microcrystalline Cellulose, citric acid, hydroxypropyl methylcellulose and the Mentholum of recipe quantity and the polyvinylpolypyrrolidone of 1/2 recipe quantity again, cross 80 mesh sieves; Add volume fraction again and be 60% ethanol water and make soft material in right amount, 24 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 24 mesh sieve granulate; The sodium bicarbonate, magnesium stearate and the aspartame that in dried granule, add residue polyvinylpolypyrrolidone and recipe quantity again, mixing, tabletting is made 1000 of carbazochrome sodium sulfonate oral disintegrating tablets altogether, and every contains carbazochrome sodium sulfonate 10mg.
Quality gained oral cavity disintegration tablet any surface finish, attractive in appearance; Hardness is 23~28 Ns and pauses; 30 mesh sieves are also passed through in complete disintegrate in 30 seconds in 37 ± 1 ℃ of water; Cool taste, sweetness, exquisiteness, no grittiness.
Embodiment 6
Prescription
All components pulverize separately during method for making will be write out a prescription except that carbazochrome sodium sulfonate becomes the fine powder of fineness more than 100 orders; 100~105 ℃ of dryings, make water content starch below 8%; With the carbazochrome sodium sulfonate of recipe quantity and dry starch mixing, pulverizing, cross 80 mesh sieves; Mix with mannitol, microcrystalline Cellulose, citric acid, hydroxypropyl methylcellulose and the Mentholum of recipe quantity and the polyvinylpolypyrrolidone of 1/2 recipe quantity again, cross 80 mesh sieves; Add volume fraction again and be 60% ethanol water and make soft material in right amount, 24 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 24 mesh sieve granulate; The sodium bicarbonate, magnesium stearate and the aspartame that in dried granule, add residue polyvinylpolypyrrolidone and recipe quantity again, mixing, tabletting is made 1000 of carbazochrome sodium sulfonate oral disintegrating tablets altogether, and every contains carbazochrome sodium sulfonate 10mg.
Quality gained oral cavity disintegration tablet any surface finish, attractive in appearance; Hardness is 25~28 Ns and pauses; 30 mesh sieves are also passed through in complete disintegrate in 28 seconds in 37 ± 1 ℃ of water; Cool taste, sweetness, exquisiteness, no grittiness.
The dissolution of carbazochrome sodium sulfonate oral disintegrating tablets of the present invention and commercially available carbazochrome sodium sulfonate ordinary tablet relatively
Method: get the carbazochrome sodium sulfonate oral disintegrating tablets of various embodiments of the present invention preparation and commercially available carbazochrome sodium sulfonate ordinary tablet respectively, with water 900mL is dissolution medium, rotating speed is that per minute 50 changes, according to two appendix XC second method operations of Chinese Pharmacopoeia version in 2005, in the time of 1,5,10,15,20,25,30,45 minute, get solution 5mL respectively, filter, get subsequent filtrate as need testing solution, measure trap at wavelength 363nm place, press C
10H
11N
4O
5Absorptance (the E of SNa
1%1 Cm) be 862 calculating dissolutions.The results are shown in following table.By table as seen, compare with commercially available carbazochrome sodium sulfonate ordinary tablet, carbazochrome sodium sulfonate oral disintegrating tablets of the present invention has characteristics such as disintegrate is fast, stripping is fast, dissolution height.
The dissolution of table carbazochrome sodium sulfonate oral disintegrating tablets and carbazochrome sodium sulfonate ordinary tablet relatively
Explanation is at last, above embodiment is only unrestricted in order to technical scheme of the present invention to be described, although by invention has been described with reference to the preferred embodiments of the present invention, but those of ordinary skill in the art is to be understood that, can make various changes to it in the form and details, and the spirit and scope of the present invention that do not depart from appended claims and limited.
Claims (9)
1. carbazochrome sodium sulfonate oral disintegrating tablets is characterized in that: composed of the following components by mass percentage: carbazochrome sodium sulfonate 1%~15%, filler 50%~90%, disintegrating agent 5%~40%, binding agent 1%~8%, lubricant 0.1%~5% and correctives 0.1%~5%.
2. carbazochrome sodium sulfonate oral disintegrating tablets according to claim 1 is characterized in that: composed of the following components by mass percentage: carbazochrome sodium sulfonate 1%~10%, filler 65%~85%, disintegrating agent 5%~20%, binding agent 2%~6%, lubricant 0.1%~1% and correctives 0.4%~1.5%.
3. carbazochrome sodium sulfonate oral disintegrating tablets according to claim 2 is characterized in that: composed of the following components by mass percentage: carbazochrome sodium sulfonate 8%~9%, filler 74%~80%, disintegrating agent 6%~12%, binding agent 3%~5%, lubricant 0.4%~0.5% and correctives 0.4%~1%.
4. according to each described carbazochrome sodium sulfonate oral disintegrating tablets of claim 1 to 3, it is characterized in that: described filler is one or more in starch, pregelatinized Starch, dextrin, Icing Sugar, lactose, mannitol, xylitol, erythritol and the microcrystalline Cellulose; Described disintegrating agent is one or more in low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, polyvinylpolypyrrolidone and the gas-producing disintegrant, and gas-producing disintegrant is made up of tartaric acid, citric acid or fumaric acid and sodium bicarbonate or sodium carbonate; Described binding agent is one or more in starch, methylcellulose, ethyl cellulose and the hydroxypropyl methylcellulose; Described lubricant is one or more in magnesium stearate, Pulvis Talci and the micropowder silica gel; Described correctives is one or more in saccharin sodium, aspartame, steviosin and the Mentholum.
5. carbazochrome sodium sulfonate oral disintegrating tablets according to claim 4 is characterized in that: described filler is one or more in starch, mannitol and the microcrystalline Cellulose; Described disintegrating agent is polyvinylpolypyrrolidone and/or gas-producing disintegrant; Described binding agent is a hydroxypropyl methylcellulose; Described lubricant is a magnesium stearate; Described correctives is Mentholum and/or aspartame.
6. carbazochrome sodium sulfonate oral disintegrating tablets according to claim 5 is characterized in that: described filler is starch, mannitol and microcrystalline Cellulose; Described disintegrating agent is polyvinylpolypyrrolidone or polyvinylpolypyrrolidone and gas-producing disintegrant, and gas-producing disintegrant is made up of citric acid and sodium bicarbonate; Described correctives is Mentholum or Mentholum and aspartame.
7. the preparation method of the described carbazochrome sodium sulfonate oral disintegrating tablets of claim 1 is characterized in that: adopt the wet granule compression tablet method, may further comprise the steps:
A, pulverizing: filler, disintegrating agent, binding agent, lubricant and correctives pulverize separately are become the fine powder of fineness more than 100 orders;
B, granulation: with carbazochrome sodium sulfonate and partially filled dose of mixing, pulverize, cross 80 mesh sieves; Again with the residue filler, in disintegrating agent, binding agent, in add the correctives mixing, cross 80 mesh sieves; Add wetting agent system soft material again, 20~40 mesh sieves are granulated, 60 ± 5 ℃ of dryings, and dried granule is crossed 20~60 mesh sieve granulate;
C, tabletting: with the dried granule behind the step b granulate with add disintegrating agent, lubricant, add the correctives mixing, tabletting promptly gets carbazochrome sodium sulfonate oral disintegrating tablets.
8. the preparation method of carbazochrome sodium sulfonate oral disintegrating tablets according to claim 7, it is characterized in that: the wetting agent among the described step b is that volume fraction is 60% ethanol water.
9. the preparation method of carbazochrome sodium sulfonate oral disintegrating tablets according to claim 7 is characterized in that: adopt 24 mesh sieves to granulate among the described step b, dried granule is crossed 24 mesh sieve granulate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101290751A CN101797235B (en) | 2010-03-19 | 2010-03-19 | Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101290751A CN101797235B (en) | 2010-03-19 | 2010-03-19 | Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101797235A true CN101797235A (en) | 2010-08-11 |
CN101797235B CN101797235B (en) | 2012-05-09 |
Family
ID=42593178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101290751A Expired - Fee Related CN101797235B (en) | 2010-03-19 | 2010-03-19 | Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101797235B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107970217A (en) * | 2016-10-25 | 2018-05-01 | 浙江京新药业股份有限公司 | Cariliprazine oral disnitegration tablet and preparation method thereof |
CN115813870A (en) * | 2022-12-21 | 2023-03-21 | 江苏吴中医药集团有限公司 | Carbazochrome sodium sulfonate tablets and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1985808A (en) * | 2006-12-20 | 2007-06-27 | 山东省医药工业研究所 | Carbazochrome sodium sulfonate slow-released tablet and its preparing method |
CN101554377A (en) * | 2008-04-09 | 2009-10-14 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate |
-
2010
- 2010-03-19 CN CN2010101290751A patent/CN101797235B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1985808A (en) * | 2006-12-20 | 2007-06-27 | 山东省医药工业研究所 | Carbazochrome sodium sulfonate slow-released tablet and its preparing method |
CN101554377A (en) * | 2008-04-09 | 2009-10-14 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate |
Non-Patent Citations (1)
Title |
---|
《药物控释新剂型》 20050430 贾伟、高文远,主编 口腔崩解片 化学工业出版社、现代生物技术与医药科技出版中心 8-15 1-9 , 第1版 1 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107970217A (en) * | 2016-10-25 | 2018-05-01 | 浙江京新药业股份有限公司 | Cariliprazine oral disnitegration tablet and preparation method thereof |
CN115813870A (en) * | 2022-12-21 | 2023-03-21 | 江苏吴中医药集团有限公司 | Carbazochrome sodium sulfonate tablets and preparation method thereof |
CN115813870B (en) * | 2022-12-21 | 2024-05-10 | 江苏吴中医药集团有限公司 | Carbazochrome sodium sulfonate tablet and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101797235B (en) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101708336B (en) | Novel medicinal premixing auxiliary material | |
EP1745775A1 (en) | Gastroretentive formulations and manufacturing process thereof. | |
CN102548542A (en) | Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles | |
CN105496977A (en) | Succinic acid trelagliptin orally-disintegrating tablets and preparing method thereof | |
CN104546770A (en) | Azilsartan orally-disintegrating tablet and preparation method thereof | |
CN102488681B (en) | Ibuprofen diphenhydramine orally disintegrating tablet and preparation method thereof | |
CN103656654A (en) | Instant orally-disintegrating tablet and its preparation method | |
Kumar et al. | Superdisintegrant: crucial elements for mouth dissolving tablets | |
JP5466880B2 (en) | Orally disintegrating tablets | |
CN101797235B (en) | Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof | |
CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
CN101361720A (en) | Nebivolol hydrochloric acid orally disintegrating tablet and preparation method thereof | |
CN101797237A (en) | Betahistine mesilate orally disintegrating tablet and preparation method thereof | |
CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
CN101690720A (en) | Carteolol orally disintegrating tablets and preparation method thereof | |
CN102512402B (en) | Novel preparation of medicine for treating gastric and duodenal ulcers and preparation method thereof | |
CN101797236B (en) | Rivastigmine orally disintegration tablet and preparation method thereof | |
JP2010202579A (en) | Acarbose-containing disintegrating preparation in oral cavity | |
CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
CN101822646B (en) | Fexofenadine hydrochloride orally disintegrating tablet and preparation method thereof | |
CN102727455A (en) | Tadalafil oral disintegrating tablet and preparation method thereof | |
CN101664393A (en) | Methylsulfonic acid pridinol oral disintegrating tablet and preparation method thereof | |
CN100417392C (en) | An effervescence tablet of cold-treating preparation and preparation method thereof | |
CN100364519C (en) | Chewing tablet of tramado hydrochloride and its preparation method | |
CN111228227A (en) | Salbutamol sulfate oral disintegrating tablet and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 Termination date: 20180319 |